RHOPRESSA Drug Patent Profile

When do Rhopressa patents expire, and what generic alternatives are available?

Rhopressa is a drug marketed by Alcon Labs Inc and is included in one NDA. There are fifteen patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-eight patent family members in fourteen countries.

The generic ingredient in RHOPRESSA is netarsudil mesylate. One supplier is listed for this compound. Additional details are available on the netarsudil mesylate profile page.

DrugPatentWatch^® Generic Entry Outlook for Rhopressa

Rhopressa was eligible for patent challenges on December 18, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 14, 2034. This may change due to patent challenges or generic licensing.

There have been seven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for RHOPRESSA

International Patents:	68
US Patents:	15
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	18
Clinical Trials:	9
Drug Prices:	Drug price information for RHOPRESSA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RHOPRESSA
What excipients (inactive ingredients) are in RHOPRESSA?	RHOPRESSA excipients list
DailyMed Link:	RHOPRESSA at DailyMed

See drug prices for RHOPRESSA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for RHOPRESSA

NDA:

208254

Dosage:

SOLUTION/DROPS;OPHTHALMIC

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for RHOPRESSA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Alcon, a Novartis Company	PHASE4
East Coast Institute for Research	PHASE4
Florida Eye Specialists	PHASE4

See all RHOPRESSA clinical trials

Pharmacology for RHOPRESSA

Drug Class	Rho Kinase Inhibitor
Mechanism of Action	Rho Kinase Inhibitors

Paragraph IV (Patent) Challenges for RHOPRESSA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RHOPRESSA	Ophthalmic Solution	netarsudil mesylate	0.02%	208254	2	2021-12-20

US Patents and Regulatory Information for RHOPRESSA

RHOPRESSA is protected by fifteen US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alcon Labs Inc	RHOPRESSA	netarsudil mesylate	SOLUTION/DROPS;OPHTHALMIC	208254-001	Dec 18, 2017		RX	Yes	Yes			Y	Y
Alcon Labs Inc	RHOPRESSA	netarsudil mesylate	SOLUTION/DROPS;OPHTHALMIC	208254-001	Dec 18, 2017		RX	Yes	Yes			Y	Y
Alcon Labs Inc	RHOPRESSA	netarsudil mesylate	SOLUTION/DROPS;OPHTHALMIC	208254-001	Dec 18, 2017		RX	Yes	Yes
Alcon Labs Inc	RHOPRESSA	netarsudil mesylate	SOLUTION/DROPS;OPHTHALMIC	208254-001	Dec 18, 2017		RX	Yes	Yes
Alcon Labs Inc	RHOPRESSA	netarsudil mesylate	SOLUTION/DROPS;OPHTHALMIC	208254-001	Dec 18, 2017		RX	Yes	Yes
Alcon Labs Inc	RHOPRESSA	netarsudil mesylate	SOLUTION/DROPS;OPHTHALMIC	208254-001	Dec 18, 2017		RX	Yes	Yes				Y

Expired US Patents for RHOPRESSA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Alcon Labs Inc	RHOPRESSA	netarsudil mesylate	SOLUTION/DROPS;OPHTHALMIC	208254-001	Dec 18, 2017
Alcon Labs Inc	RHOPRESSA	netarsudil mesylate	SOLUTION/DROPS;OPHTHALMIC	208254-001	Dec 18, 2017
Alcon Labs Inc	RHOPRESSA	netarsudil mesylate	SOLUTION/DROPS;OPHTHALMIC	208254-001	Dec 18, 2017
Alcon Labs Inc	RHOPRESSA	netarsudil mesylate	SOLUTION/DROPS;OPHTHALMIC	208254-001	Dec 18, 2017
Alcon Labs Inc	RHOPRESSA	netarsudil mesylate	SOLUTION/DROPS;OPHTHALMIC	208254-001	Dec 18, 2017

International Patents for RHOPRESSA

When does loss-of-exclusivity occur for RHOPRESSA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

Denmark

European Patent Office

Finland

Hungary

Japan

Netherlands

Poland

Portugal

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering RHOPRESSA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2010241996
Australia	2010242800
Australia	2016201754
Australia	2017248440
Australia	2019210632
Australia	2021204320

Supplementary Protection Certificates for RHOPRESSA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3053913	301038	Netherlands		PRODUCT NAME: NETARSUDIL, OF EEN ZOUT OF SOLVAAAT DAARVAN, IN HET BIJZONDER NETARSUDILMESYLAAT; REGISTRATION NO/DATE: EU/1/19/1400 20191121
3053913	122020000016	Germany		PRODUCT NAME: NETARSUDIL, ODER EIN ENANTIOMER, DIASTEREOMER, SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/19/1400 20191119
3053913	2020C/510	Belgium		PRODUCT NAME: RHOKIINSA - NETARSUDIL; AUTHORISATION NUMBER AND DATE: EU/1/19/1400 20191121
3053913	132020000000043	Italy		PRODUCT NAME: NETARSUDIL(RHOKIINSA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1400, 20191121
3053913	2020/016	Ireland		PRODUCT NAME: NETARSUDIL, OR AN ENANTIOMER, DIASTEREOMER, SALT OR SOLVATE THEREOF; REGISTRATION NO/DATE: EU/1/19/1400 20191121
3053913	C202030018	Spain		PRODUCT NAME: NETARSUDIL O UN ENANTIOMERO, DIASTEREOMERO, SAL O SOLVATO DEL MISMO.; NATIONAL AUTHORISATION NUMBER: EU/1/19/1400; DATE OF AUTHORISATION: 20191119; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1400; DATE OF FIRST AUTHORISATION IN EEA: 20191119

Last updated: July 12, 2026

Rhopressa (Netarsudil Ophthalmic Solution) Market Dynamics and Financial Trajectory: Exclusivity, Competitive Landscape, and Revenue Outlook

Executive summary: Rhopressa (netarsudil ophthalmic solution) is a niche ophthalmology asset in glaucoma and ocular hypertension. Post-launch volume has been shaped by payer restrictions, formulary placement, sequence-of-therapy positioning versus prostaglandin analogs and beta blockers, and tolerability constraints typical for Rho-kinase inhibition (ocular redness, conjunctival hyperemia). Financial trajectory is primarily driven by US net pricing dynamics, pharmacy benefit management (PBM) contracting, and competitive pressure from newer fixed-combination regimens and adjacent glaucoma mechanisms. Patent and exclusivity timelines, plus generic entry risk, remain key swing factors for long-run profitability.

---

What is Rhopressa (netarsudil) used for and how does this drive market uptake?

Rhopressa is an ophthalmic solution indicated for:

• Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Demand drivers

1. Therapy positioning: Netarsudil is generally used after first-line prostaglandin analogs and/or when additional IOP lowering is required. Uptake depends on how payers define “step therapy” and whether clinicians use it as add-on therapy.
2. Mechanism fit: As a Rho-kinase inhibitor, netarsudil targets trabecular outflow and is used to extend IOP control in patients not adequately controlled on existing regimens.
3. Tolerability: Ocular adverse events are a recurring limiter. Formulary adoption correlates with prescriber comfort balancing efficacy against hyperemia and redness.

Commercial implication: The product’s revenue ceiling is constrained by (a) the incremental nature of late-line add-on demand and (b) adherence and persistence issues tied to ocular tolerability.

---

How has Rhopressa performed financially since launch?

Executive answer: Rhopressa’s financial trajectory follows a pattern typical for specialty ophthalmology agents: initial growth concentrated in US channels followed by stabilization under formulary friction and competition within glaucoma therapy algorithms.

Key forces shaping financial outcomes:

• Net price vs list price: US ophthalmology spend is highly sensitive to PBM rebates, manufacturer copay structures, and contract terms. As formulary placement matures, net revenue often grows slower than gross sales.
• Share dynamics: Clinical differentiation matters, but glaucoma patients often cycle through multiple classes. Netarsudil’s long-term share depends on where it sits in the sequence of therapy for different payer segments (commercial vs Medicare Part D).
• Channel mix: Specialty distribution and pharmacy benefit routing can change over time, affecting realized revenue and gross-to-net conversion.

What to track in financials

• Gross sales trend by quarter (or year)
• Gross-to-net components (rebates, chargebacks, prompt pay)
• Specialty pharmacy mix and commercial coverage expansion
• Prescription counts and average days supply trends

Business read-through: If net coverage improves and persistence holds, sales can climb even without radical mechanism shifts. If intolerance or step-therapy barriers dominate, revenues plateau.

---

What patents protect Rhopressa (netarsudil) and what expiration dates matter commercially?

Executive answer: Rhopressa’s exclusion landscape is typically anchored in composition-of-matter and formulation-related patents covering netarsudil (or related crystalline forms) and ophthalmic solution compositions, plus potential method-of-use coverage tied to IOP reduction in glaucoma/ocular hypertension.

Commercial relevance

• Any composition-of-matter or formulation expiration drives the earliest realistic date for generic entry, while method-of-use patents can delay label-equivalent competition depending on Paragraph IV outcomes and settlement terms.
• Orange Book status listings determine whether generic challengers must litigate specific claims for immediate launch risk.

Why this matters for revenue

• Netarsudil’s long-run profitability is exposed to a step-change around generic entry windows (or at least around loss of exclusivity for one or more claim sets).
• Even without full generic entry, patent weakness can invite “authorized generics,” label workarounds, or competitive suppression via payer steering.

---

What is the Orange Book status of Rhopressa and what does it imply for generic entry risk?

Executive answer: The Orange Book listing governs whether generic manufacturers face patent litigation for an ANDA that references Rhopressa. For brand holders, the presence, number, and type of listed patents (drug substance, drug product, method-of-use) determines both the likelihood of successful Paragraph IV challenges and the probability of settlement.

How to interpret Orange Book risk

• Fewer listed patents or only weak late-expiring claims typically increases generic pressure.
• Multiple drug product/formulation patents can slow entry if claim-by-claim invalidity/ noninfringement arguments fail.
• Method-of-use patents can allow partial “at-risk” launch only if the ANDA can avoid the protected indication or carve out claims.

Commercial implication: Generic entry risk is not only about the earliest expiration date. It is about whether claim subsets can be designed around and how quickly a challenger can win (or settle) for launch.

---

When does Rhopressa lose exclusivity: timeline and key milestone dates?

Executive answer: Rhopressa’s exclusivity timeline is determined by the intersection of patent expirations (drug substance, formulation, method-of-use) and regulatory exclusivity attached to the NDA.

Milestone logic for revenue planning

1. Earliest patent expiration sets the earliest “legal” entry risk for ANDA litigation.
2. Regulatory exclusivity expiration can delay even if patents weaken.
3. Post-expiration market erosion depends on payer substitution behavior and whether the generic is AB-rated and priced aggressively.

Business planning use case: Revenue forecasts should model multiple entry scenarios: first generic launch, subsequent entrants, and increased rebates that follow competitive normalization.

---

What generic entry risks exist for Rhopressa and how would launch timing affect sales?

Executive answer: Generic entry risk is most acute once the brand’s enforceable patent claims are no longer sufficient to block an ANDA launch, either through expiration, successful Paragraph IV litigation, or settlement.

Launch timing effects

• 3- to 6-month cliff risk: If an ANDA is approved and a generic launches, ophthalmology revenues can decline quickly due to payer switching.
• Rebate renegotiation: Brands often respond with price concessions and contracting changes that compress margins even before large volume migration.
• Persistence impact: Even with generic availability, persistence can improve for some patients if copay assistance or tolerability is favorable. But price-based switching is the primary volume driver.

Business read-through: A generic launch typically drives a sharp gross-to-net and margin reset, then stabilizes at a lower plateau if multiple suppliers compete.

---

Has Rhopressa faced Paragraph IV challenges, ANDA litigation, or settlement agreements?

Executive answer: For an ophthalmology brand, the key litigation question is whether challengers have attacked specific Orange Book-listed claims via Paragraph IV certifications and whether settlements restrict launch dates or require design-to-avoid workarounds.

Litigation-driven revenue impacts

• No settlement: At-risk launch can accelerate revenue loss and force rapid contracting.
• Carve-outs and design-around: Brands can preserve some market share if generics avoid claims affecting formulation or method-of-use.
• 180-day exclusivity for first filer: A settlement that delays launch until another event can shift market erosion timing by months to years.

---

Which companies are competing against Rhopressa in glaucoma and ocular hypertension?

Executive answer: Rhopressa competes within glaucoma IOP-lowering classes, not only against direct Rho-kinase inhibition products. The main competitive set includes:

• Prostaglandin analogs (often first-line)
• Beta-blockers and alpha agonists (add-on or alternate lines)
• Carbonic anhydrase inhibitors (add-on)
• Fixed combinations that can displace add-on monotherapy
• Other emerging agents targeting outflow pathways

How competitive dynamics affect market share

• Formulary design: Many payers prefer regimens that reduce dosing frequency or avoid more frequent ocular side effects.
• Combination strategy: Fixed combinations can outcompete monotherapy by simplifying adherence and lowering net cost per controlled IOP regimen.

---

How does Rhopressa compare with other IOP-lowering therapies in market adoption?

Executive answer: Netarsudil’s adoption depends on relative positioning versus first-line agents and whether it is used as add-on after inadequate response.

Comparison axes that move formulary decisions

• Dosing frequency and convenience
• Efficacy profile in lowering IOP
• Incidence and severity of ocular hyperemia/redness
• Patient persistence and real-world tolerability
• Economics: net price after rebates and copay assistance, and payer criteria for step edits

Commercial implication: Even if clinical efficacy is compelling, strong real-world adherence and tolerability determine durable share.

---

What formulations are protected by Rhopressa’s patent estate?

Executive answer: Rhopressa’s protection typically extends to the ophthalmic solution format, including formulation parameters that stabilize netarsudil and ensure delivery performance.

Why formulation patents matter

• Generic entry often requires pharmaceutical equivalence plus bioavailability equivalence (for ophthalmics via relevant endpoints).
• Formulation claim coverage can force challengers into longer litigation or settlement if they cannot prove noninfringement.

Revenue exposure link: If formulation patents hold, generic erosion is delayed and brand share remains protected longer.

---

What method-of-use patents could limit generic switching even after drug substance expiration?

Executive answer: If method-of-use patents tie netarsudil to specific treatment regimens or patient populations, generics can be constrained to carve-outs or labeling changes, reducing immediate AB-equivalence substitutability.

Payer/labeling impact

• Pharmacy substitution is driven by label match and payer policy.
• If generic labeling is carved out, substitution can be delayed or limited to specific clinical scenarios.

---

What manufacturing and IP barriers could slow down generic competition?

Executive answer: For ophthalmic solutions, manufacturing barriers are less about large-scale API production and more about:

• maintaining formulation stability
• meeting sterility and quality attributes
• demonstrating equivalence in regulatory submission

IP barriers

• formulation composition claims
• process claims (if present)
• method-of-use claims impacting label scope

Commercial read-through: Even with legal permission, execution risks can delay actual availability, extending brand revenues.

---

How do FDA regulatory events affect Rhopressa sales trajectory?

Executive answer: Sales in ophthalmics can shift with:

• label updates
• changes in safety labeling
• REMS-type constraints (if any, though netarsudil is typically managed without a broad REMS framework)
• postmarketing requirements that alter clinical comfort

Revenue mechanics

• New labeling can expand or narrow prescriber usage.
• Safety signals can affect persistence and payer acceptance, changing prescription volumes even without a competitor launch.

---

What settlement outcomes matter most for Rhopressa revenue protection?

Executive answer: If litigation occurred, the settlement’s core terms are usually:

• agreed launch dates for generic challengers
• design-around restrictions (formulation or labeling)
• indemnity and market allocation
• duration and geographic scope

Revenue protection logic

• settlements can preserve exclusivity longer than the “headline” expiration date for the most challenged patents
• settlement can also limit how quickly subsequent entrants appear

---

How does Rhopressa’s market outlook change under multiple generic entry scenarios?

Executive answer: Model revenue under at least three tracks:

1. Delayed entry: patents hold or litigation runs long. Revenue stabilizes and gradually grows with coverage expansion.
2. One entrant: first generic launch triggers a decline; margins compress but plateau after PBM switching stabilizes.
3. Multiple entrants: faster erosion and steeper gross-to-net pressure, forcing steeper price reductions and possibly re-contracting.

Quantification framework (used for forecasting)

• current annualized prescriptions
• expected generic share at 6, 12, 24 months
• gross-to-net delta pre and post entry
• net price and contracting elasticity by channel

(Without product-specific financial figures and Orange Book tables in the record provided here, only the scenario logic can be stated.)

---

Key tables for decision-making

Table: Commercial levers affecting Rhopressa net revenue

Lever	What moves	Where it shows up	Revenue direction
PBM formulary placement	tier status, preferred status, step edits	gross-to-net and prescription volume	up or down
Step therapy rules	prior authorization, required failure of alternatives	persistence and new scripts	down
Tolerability profile	redness/hyperemia burden	adherence and discontinuation	down
Contracting and rebates	realized net price	gross-to-net	up or down
Generic entry timing	launch approval and stocking	sharp revenue drop after launch	down
Multi-entrant environment	number of suppliers	margin compression	down
Label changes	safety updates, expansion	prescriber comfort, persistence	mixed

---

Key Takeaways

• Rhopressa’s growth is constrained by add-on positioning in glaucoma algorithms and by payer step-therapy dynamics.
• Financial trajectory is dominated by gross-to-net performance, persistence tied to ocular tolerability, and coverage expansion in commercial and Medicare channels.
• Generic entry risk is the primary long-term revenue swing factor and depends on the Orange Book patent set and the outcome of any Paragraph IV challenges and settlements.
• Forecasting should use multi-scenario modeling around exclusivity loss, legal blocking, and the speed of payer switching post-launch.

---

FAQs

1. What payer restrictions most affect netarsudil prescriptions? Step edits, prior authorization criteria, and tier placement that require failure of first-line prostaglandin analogs.
2. Does generic entry require the ANDA to match Rhopressa’s exact indications? Yes, AB-rating and label carve-outs can delay substitution if method-of-use patents limit labeling.
3. How fast do ophthalmic glaucoma revenues typically erode after generic launch? Often within 3 to 6 months, driven by PBM switching and pharmacy benefit routing.
4. Can formulation differences delay generic substitution even after patent expiry? Yes, formulation-related patents and design-around constraints can slow or limit AB-equivalent availability.
5. What competitive pressure is strongest versus Rhopressa? Fixed combinations and first-line agents that simplify dosing or reduce ocular tolerability burdens, impacting add-on selection.

---

References

No sources were provided in the prompt record, and no authoritative citationable materials (Orange Book listings, FDA approvals, litigation dockets, or financial statements) were included here.

DrugChatter Q&A for RHOPRESSA

When does rhopressa go generic?
Rhopressa patent international?
Rhopressa gouttte prix amerique?
Price of rhopressa eye drops?
Why is rhopressa so expensive?